2026-06-27T22:43:24Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1082132025-03-18T14:02:42Zcom_20.500.14352_14col_20.500.14352_15

Alonso Miguel, Daniel Fiering, Steven Arias Pulido, Hugo 2024-09-17T16:01:05Z 2024-09-17T16:01:05Z 2022-09-13 Alonso-Miguel, D., Fiering, S., & Arias-Pulido, H. (2022). Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes. Cells, 11(18), 2850. https://doi.org/10.3390/cells11182850 10.3390/cells11182850 https://hdl.handle.net/20.500.14352/108213 2073-4409 https://doi.org/10.3390/cells11182850 36139425 Inflammatory breast cancer (IBC) is highly metastatic at the onset of the disease with no IBC-specific treatments, resulting in dismal patient survival. IBC treatment is a clear unmet clinical need. This commentary highlights findings from a recent seminal approach in which pembrolizumab, a checkpoint inhibitor against programmed cell death protein 1 (PD-1), was provided to a triple-negative IBC patient as a neoadjuvant immune therapy combined with anthracycline-taxane-based chemotherapy. We highlight the findings of the case report and offer a perspective on taking a proactive approach to deploy approved immune checkpoint inhibitors. On the basis of our recently published research study, we propose in situ vaccination with direct injection of immunostimulatory agents into the tumor as an option to improve outcomes safely, effectively, and economically for IBC patients. eng http://creativecommons.org/licenses/by/4.0/ open access Attribution 4.0 International Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes journal article